
Ralf Schirrmacher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5792873/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	18F-Labeling of Peptides by means of an Organosilicon-Based Fluoride Acceptor. Angewandte Chemie - International Edition, 2006, 45, 6047-6050.	7.2	205
2	The Temporal Dynamics of Poststroke Neuroinflammation: A Longitudinal Diffusion Tensor Imaging–Guided PET Study with ¹¹ C-PK11195 in Acute Subcortical Stroke. Journal of Nuclear Medicine, 2010, 51, 1404-1412.	2.8	129
3	Recent Developments and Trends in 18F-Radiochemistry: Syntheses and Applications. Mini-Reviews in Organic Chemistry, 2007, 4, 317-329.	0.6	113
4	Where in-vivo imaging meets cytoarchitectonics: The relationship between cortical thickness and neuronal density measured with high-resolution [18F]flumazenil-PET. NeuroImage, 2011, 56, 951-960.	2.1	113
5	Synthesis ofp-(Di-tert-butyl[18F]fluorosilyl)benzaldehyde ([18F]SiFA-A) with High Specific Activity by Isotopic Exchange: A Convenient Labeling Synthon for the18F-Labeling of N-amino-oxy Derivatized Peptides. Bioconjugate Chemistry, 2007, 18, 2085-2089.	1.8	94
6	89Zr, a Radiometal Nuclide with High Potential for Molecular Imaging with PET: Chemistry, Applications and Remaining Challenges. Molecules, 2013, 18, 6469-6490.	1.7	92
7	Multimerization of cRGD Peptides by Click Chemistry: Synthetic Strategies, Chemical Limitations, and Influence on Biological Properties. ChemBioChem, 2010, 11, 2168-2181.	1.3	84
8	In Vivo Evaluation of ¹⁸ F-SiFA <i>lin</i> –Modified TATE: A Potential Challenge for ⁶⁸ Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET. Journal of Nuclear Medicine, 2015, 56, 1100-1105.	2.8	83
9	One-Step ¹⁸ F-Labeling of Carbohydrate-Conjugated Octreotate-Derivatives Containing a Silicon-Fluoride-Acceptor (SiFA): In Vitro and in Vivo Evaluation as Tumor Imaging Agents for Positron Emission Tomography (PET). Bioconjugate Chemistry, 2010, 21, 2289-2296.	1.8	74
10	One-step 18F-labeling of peptides for positron emission tomography imaging using the SiFA methodology. Nature Protocols, 2012, 7, 1946-1955.	5.5	74
11	From Unorthodox to Established: The Current Status of ¹⁸ F-Trifluoroborate- and ¹⁸ F-SiFA-Based Radiopharmaceuticals in PET Nuclear Imaging. Bioconjugate Chemistry, 2016, 27, 267-279.	1.8	66
12	Kit-Like ¹⁸ F-Labeling of Proteins: Synthesis of 4-(Di- <i>tert</i> -butyl[¹⁸ F]fluorosilyl)benzenethiol (Si[¹⁸ F]FA-SH) Labeled Rat Serum Albumin for Blood Pool Imaging with PET. Bioconjugate Chemistry, 2009, 20, 317-321.	1.8	64
13	<i>para</i> â€Functionalized Arylâ€diâ€ <i>tert</i> â€butylfluorosilanes as Potential Labeling Synthons for ¹⁸ F Radiopharmaceuticals. Chemistry - A European Journal, 2009, 15, 2140-2147.	1.7	62
14	Bimodal Imaging Probes for Combined PET and OI: Recent Developments and Future Directions for Hybrid Agent Development. BioMed Research International, 2014, 2014, 1-13.	0.9	61
15	Parametric mapping of binding in human brain of D2 receptor ligands of different affinities. Journal of Nuclear Medicine, 2005, 46, 964-72.	2.8	61
16	Establishment and functional validation of a structural homology model for human DNA methyltransferase 1. Biochemical and Biophysical Research Communications, 2003, 306, 558-563.	1.0	54
17	Inhibition of O6-Methylguanine-DNA Methyltransferase by Glucose-Conjugated Inhibitors: Comparison with Nonconjugated Inhibitors and Effect on Fotemustine and Temozolomide-Induced Cell Death. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 585-593.	1.3	54
18	A Universally Applicable ⁶⁸ Ga-Labeling Technique for Proteins. Journal of Nuclear Medicine, 2011, 52, 586-591.	2.8	53

#	Article	IF	CITATIONS
19	Rapid ¹⁸ F-Labeling and Loading of PEGylated Gold Nanoparticles for in Vivo Applications. Bioconjugate Chemistry, 2014, 25, 1143-1150.	1.8	53
20	Recent Advances in ¹⁸ F Radiochemistry: A Focus on B- ¹⁸ F, Si- ¹⁸ F, Al- ¹⁸ F, and C- ¹⁸ F Radiofluorination via Spirocyclic Iodonium Ylides. Journal of Nuclear Medicine, 2018, 59, 568-572.	2.8	50
21	Opioid Receptor PET Reveals the Psychobiologic Correlates of Reward Processing. Journal of Nuclear Medicine, 2008, 49, 1257-1261.	2.8	48
22	Generation of Novel Single-Chain Antibodies by Phage-Display Technology to Direct Imaging Agents Highly Selective to Pancreatic β- or α-Cells In Vivo. Diabetes, 2009, 58, 2324-2334.	0.3	48
23	Oxalic Acid Supported Si– ¹⁸ F-Radiofluorination: One-Step Radiosynthesis of <i>N</i> -Succinimidyl 3-(Di- <i>tert</i> -butyl[¹⁸ F]fluorosilyl)benzoate ([¹⁸ F]SiFB) for Protein Labeling. Bioconjugate Chemistry, 2012, 23, 106-114.	1.8	47
24	[18F]Azadibenzocyclooctyne ([18F]ADIBO): A biocompatible radioactive labeling synthon for peptides using catalyst free [3+2] cycloaddition. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6987-6991.	1.0	43
25	A Nutritional Perspective of Ketogenic Diet in Cancer: A Narrative Review. Journal of the Academy of Nutrition and Dietetics, 2018, 118, 668-688.	0.4	43
26	Synthesis and in Vitro Evaluation of Biotinylated RG108:Â A High Affinity Compound for Studying Binding Interactions with Human DNA Methyltransferases. Bioconjugate Chemistry, 2006, 17, 261-266.	1.8	42
27	Preparation of Water-Soluble Maleimide-Functionalized 3 nm Gold Nanoparticles: A New Bioconjugation Template. Langmuir, 2012, 28, 5508-5512.	1.6	42
28	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – <i>Part II</i> . Expert Opinion on Therapeutic Patents, 2017, 27, 831-849.	2.4	41
29	Basal opioid receptor binding is associated with differences in sensory perception in healthy human subjects: A [18F]diprenorphine PET study. NeuroImage, 2010, 49, 731-737.	2.1	40
30	Silicon-[18F]Fluorine Radiochemistry: Basics, Applications and Challenges. Applied Sciences (Switzerland), 2012, 2, 277-302.	1.3	40
31	Efficient alkali iodide promoted 18F-fluoroethylations with 2-[18F]fluoroethyl tosylate and 1-bromo-2-[18F]fluoroethane. Tetrahedron Letters, 2003, 44, 9165-9167.	0.7	38
32	¹⁸ F-Labeled Silicon-Based Fluoride Acceptors: Potential Opportunities for Novel Positron Emitting Radiopharmaceuticals. BioMed Research International, 2014, 2014, 1-20.	0.9	38
33	Small Prosthetic Groups in 18 F-Radiochemistry: Useful Auxiliaries for the Design of 18 F-PET Tracers. Seminars in Nuclear Medicine, 2017, 47, 474-492.	2.5	38
34	Synthesis and in Vitro and in Vivo Evaluation of SiFA-Tagged Bombesin and RGD Peptides as Tumor Imaging Probes for Positron Emission Tomography. Bioconjugate Chemistry, 2014, 25, 738-749.	1.8	36
35	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – <i>Part I</i> . Expert Opinion on Therapeutic Patents, 2017, 27, 733-751.	2.4	36
36	Identification of [¹⁸ F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging. Journal of Medicinal Chemistry, 2018, 61, 1737-1743.	2.9	36

#	Article	lF	CITATIONS
37	Automated synthesis of PET radiotracers by copperâ€mediated ¹⁸ Fâ€fluorination of organoborons: Importance of the order of addition and competing protodeborylation. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 228-236.	0.5	36
38	Improved work-up procedure for the production of [18F]flumazenil and first results of its use with a high-resolution research tomograph in human stroke. Nuclear Medicine and Biology, 2009, 36, 721-727.	0.3	35
39	Synthesis and in vitro evaluation of (S)-2-([11C]methoxy)-4-[3-methyl-1-(2-piperidine-1-yl-phenyl)-butyl-carbamoyl]-benzoic acid ([11C]methoxy-repaglinide): a potential β-cell imaging agent. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5205-5209.	1.0	34
40	N-(4-(di-tert-butyl[18F]fluorosilyl)benzyl)-2-hydroxy-N,N-dimethylethylammonium bromide ([18F]SiFAN+Brâ^²): A novel lead compound for the development of hydrophilic SiFA-based prosthetic groups for 18F-labeling. Journal of Fluorine Chemistry, 2011, 132, 27-34.	0.9	34
41	Protein labeling with the labeling precursor [18F]SiFA-SH for positron emission tomography. Nature Protocols, 2012, 7, 1964-1969.	5.5	34
42	External awareness and GABA-A multimodal imaging study combining fMRI and [¹⁸ F]flumazenil-PET. Human Brain Mapping, 2014, 35, 173-184.	1.9	34
43	Rapid in situ synthesis of [11C]methyl azide and its application in 11C click-chemistry. Tetrahedron Letters, 2008, 49, 4824-4827.	0.7	32
44	5-(4-((4-[18F]fluorobenzyl)oxy)-3-methoxybenzyl)pyrimidine-2,4-diamine: A selective dual inhibitor for potential PET imaging of Trk/CSF-1R. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4784-4790.	1.0	32
45	PESIN Multimerization Improves Receptor Avidities and <i>in Vivo</i> Tumor Targeting Properties to GRPR-Overexpressing Tumors. Bioconjugate Chemistry, 2014, 25, 489-500.	1.8	32
46	Synthesis of a Tyr3-octreotate conjugated closo-carborane [HC2B10H10]: a potential compound for boron neutron capture therapy. Tetrahedron Letters, 2003, 44, 9143-9145.	0.7	27
47	Synthesis of [18F]SiFB: a prosthetic group for direct protein radiolabeling for application in positron emission tomography. Nature Protocols, 2012, 7, 1956-1963.	5.5	27
48	Synthesis of 3-chloro-6-((4-(di-tert-butyl[¹⁸ F]fluorosilyl)-benzyl)oxy)-1,2,4,5-tetrazine ([¹⁸ F]SiFA-OTz) for rapid tetrazine-based ¹⁸ F-radiolabeling. Chemical Communications, 2015, 51, 12415-12418.	2.2	27
49	Synthesis of131I-Labeled Glucose-Conjugated Inhibitors ofO6-Methylguanine-DNA Methyltransferase (MGMT) and Comparison with Nonconjugated Inhibitors as Potential Tools for in Vivo MGMT Imaging. Journal of Medicinal Chemistry, 2006, 49, 263-272.	2.9	26
50	Facile Covalent Modification of a Highly Ordered Pyrolytic Graphite Surface via an Inverse Electron Demand Diels–Alder Reaction under Ambient Conditions. Chemistry of Materials, 2014, 26, 5058-5062.	3.2	25
51	Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging. Molecules, 2015, 20, 22000-22027.	1.7	25
52	Synthesis of 2-amino-6-(2-[18F]fluoro-pyridine-4-ylmethoxy)-9-(octyl-β-d-glucosyl)-purine: a novel radioligand for positron emission tomography studies of the O6-methylguanine-DNA methyltransferase (MGMT) status of tumour tissue. Tetrahedron Letters, 2002, 43, 6301-6304.	0.7	24
53	Syntheses and Evaluation of Carbon-11- and Fluorine-18-Radiolabeled pan-Tropomyosin Receptor Kinase (Trk) Inhibitors: Exploration of the 4-Aza-2-oxindole Scaffold as Trk PET Imaging Agents. ACS Chemical Neuroscience, 2015, 6, 260-276.	1.7	23
54	Application of tris-allyl-DOTA in the preparation of DOTA–peptide conjugates. Tetrahedron Letters, 2006, 47, 5985-5988.	0.7	22

#	Article	IF	CITATIONS
55	DOTA derivatives for site-specific biomolecule-modification via click chemistry: Synthesis and comparison of reaction characteristics. Bioorganic and Medicinal Chemistry, 2011, 19, 3864-3874.	1.4	22
56	GABAA Receptors Predict Aversion-Related Brain Responses: An fMRI-PET Investigation in Healthy Humans. Neuropsychopharmacology, 2013, 38, 1438-1450.	2.8	21
57	Tropomyosin receptor kinase inhibitors: an updated patent review for 2016–2019. Expert Opinion on Therapeutic Patents, 2020, 30, 325-339.	2.4	21
58	Towards tropomyosin-related kinase B (TrkB) receptor ligands for brain imaging with PET: Radiosynthesis and evaluation of 2-(4-[18F]fluorophenyl)-7,8-dihydroxy-4H-chromen-4-one and 2-(4-([N-methyl-11C]-dimethylamino)phenyl)-7,8-dihydroxy-4H-chromen-4-one. Bioorganic and Medicinal Chemistry, 2013, 21, 7816-7829.	1.4	20
59	A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human. Journal of Medicinal Chemistry, 2017, 60, 6897-6910.	2.9	20
60	t-Bu2SiF-Derivatized D2-Receptor Ligands: The First SiFA-Containing Small Molecule Radiotracers for Target-Specific PET-Imaging. Molecules, 2011, 16, 7458-7479.	1.7	19
61	GABAA receptors in visual and auditory cortex and neural activity changes during basic visual stimulation. Frontiers in Human Neuroscience, 2012, 6, 337.	1.0	19
62	Development of subnanomolar radiofluorinated (2-pyrrolidin-1-yl)imidazo[1,2-b]pyridazine pan-Trk inhibitors as candidate PET imaging probes. MedChemComm, 2015, 6, 2184-2193.	3.5	19
63	First-in-Human Brain Imaging of [¹⁸ F]TRACK, a PET tracer for Tropomyosin Receptor Kinases. ACS Chemical Neuroscience, 2019, 10, 2697-2702.	1.7	19
64	SiFA-Modified Phenylalanine: A Key Compound for the Efficient Synthesis of 18F-Labelled Peptides. European Journal of Inorganic Chemistry, 2011, 2011, 2238-2246.	1.0	18
65	Radiolabeled Heterobivalent Peptidic Ligands: an Approach with High Future Potential for in vivo Imaging and Therapy of Malignant Diseases. ChemMedChem, 2013, 8, 883-890.	1.6	18
66	Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors. Molecular Pharmaceutics, 2015, 12, 3924-3934.	2.3	18
67	¹⁸ F-Radiolabeling and <i>In Vivo</i> Analysis of SiFA-Derivatized Polymeric Core–Shell Nanoparticles. Bioconjugate Chemistry, 2018, 29, 89-95.	1.8	18
68	Gastrin-Releasing Peptide Receptor- and Prostate-Specific Membrane Antigen-Specific Ultrasmall Gold Nanoparticles for Characterization and Diagnosis of Prostate Carcinoma via Fluorescence Imaging. Bioconjugate Chemistry, 2018, 29, 1525-1533.	1.8	17
69	Radiosynthesis of [18F]SiFAlin-TATE for clinical neuroendocrine tumor positron emission tomography. Nature Protocols, 2020, 15, 3827-3843.	5.5	17
70	Radiosynthesis and Preclinical Evaluation of18F-Fluoroglycosylated Octreotate for Somatostatin Receptor Imaging. Bioconjugate Chemistry, 2016, 27, 2707-2714.	1.8	16
71	Automated production of [18F]SiTATE on a Scintomics GRPâ,,¢ platform for PET/CT imaging of neuroendocrine tumors. Nuclear Medicine and Biology, 2020, 88-89, 86-95.	0.3	16
72	Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy. Pharmaceuticals, 2020, 13, 173.	1.7	16

#	Article	IF	CITATIONS
73	Automated synthesis of [18F]Ga-rhPSMA-7/ -7.3: results, quality control and experience from more than 200 routine productions. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 4.	1.8	16
74	Positron emission tomography in the assessment of left ventricular function in healthy rats: A comparison of four imaging methods. Journal of Nuclear Cardiology, 2013, 20, 262-274.	1.4	15
75	Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3571-3581.	3.3	15
76	Design, synthesis and inÂvitro evaluation of heterobivalent peptidic radioligands targeting both GRP- and VPAC1-Receptors concomitantly overexpressed on various malignancies – Is the concept feasible?. European Journal of Medicinal Chemistry, 2018, 155, 84-95.	2.6	14
77	Direct one-step labeling of cysteine residues on peptides with [11C]methyl triflate for the synthesis of PET radiopharmaceuticals. Amino Acids, 2013, 45, 1097-1108.	1.2	13
78	Which Aspects of Stroke Do Animal Models Capture? A Multitracer Micro-PET Study of Focal Ischemia with Endothelin-1. Cerebrovascular Diseases, 2016, 41, 139-147.	0.8	13
79	Recent Advances in the Clinical Translation of Silicon Fluoride Acceptor (SiFA) 18F-Radiopharmaceuticals. Pharmaceuticals, 2021, 14, 701.	1.7	13
80	iEDDA Conjugation Reaction in Radiometal Labeling of Peptides with ⁶⁸ Ga and ⁶⁴ Cu: Unexpected Findings. ACS Omega, 2018, 3, 14039-14053.	1.6	12
81	Side-by-Side Comparison of Five Chelators for 89Zr-Labeling of Biomolecules: Investigation of Chemical/Radiochemical Properties and Complex Stability. Cancers, 2021, 13, 6349.	1.7	12
82	Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y1)- and GRP-Receptors—An Improvement for Breast Cancer Imaging?. Pharmaceuticals, 2018, 11, 65.	1.7	11
83	Simple and convenient radiolabeling of proteins using a prelabeling-approach with thiol-DOTA. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1926-1929.	1.0	10
84	Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2771-2775.	1.0	10
85	Synthesis and preliminary evaluation of (R,R)(S,S) 5-(2-(2-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylethylamino)-1-hydroxyethyl)-benzene-1,3-diol ([18F]FEFE) for the in vivo visualisation and quantification of the I²2-adrenergic receptor status in lung. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2687-2692.	1.0	9
86	Fully automated SPE-based synthesis and purification of 2-[18F]fluoroethyl-choline for human use. Nuclear Medicine and Biology, 2011, 38, 165-170.	0.3	9
87	Alpha selective epoxide opening with 18Fâ^: synthesis of 4-(3-[18F]fluoro-2-hydroxypropoxy)benzaldehyde ([18F]FPB) for peptide labeling. Tetrahedron Letters, 2011, 52, 1973-1976.	0.7	9
88	Design of brain imaging agents for positron emission tomography: do large bioconjugates provide an opportunity for <i>in vivo</i> brain imaging?. Future Medicinal Chemistry, 2013, 5, 1621-1634.	1.1	9
89	Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging. Pharmaceuticals, 2019, 12, 7.	1.7	9
90	An approach to the evaluation of the activity of the DNA repair enzyme O6-methylguanine-DNA-methyl-transferase in tumor tissue in vivo: syntheses of 6-benzyloxy-9-(2-[18F]fluoroethyl)-9H-purin-2-yl-amine and 6-benzyloxy-7-(2-[18F]fluoroethyl)-7H-purin-2-yl-amine. Applied Radiation and Isotopes, 2002, 56, 511-517.	0.7	8

#	Article	IF	CITATIONS
91	Efficient radiosynthesis and preclinical evaluation of [¹⁸ F]FOMPyD as a positron emission tomography tracer candidate for TrkB/C receptor imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2020, 63, 144-150.	0.5	8
92	Development and biological evaluation of[18F]FMN3PA & [18F]FMN3PU for leucine-rich repeat kinase 2 (LRRK2) inÂvivo PET imaging. European Journal of Medicinal Chemistry, 2021, 211, 113005.	2.6	8
93	PET Imaging of Meningioma Using the Novel SSTR-Targeting Peptide 18F-SiTATE. Clinical Nuclear Medicine, 2021, 46, 667-668.	0.7	8
94	Evaluation of an automated double-synthesis module: efficiency and reliability of subsequent radiosyntheses of FHBG and FLT. Nuclear Medicine and Biology, 2012, 39, 586-592.	0.3	7
95	Shuttle–Cargo Fusion Molecules of Transport Peptides and the hD _{2/3} Receptor Antagonist Fallypride: A Feasible Approach To Preserve Ligand–Receptor Binding?. Journal of Medicinal Chemistry, 2014, 57, 4368-4381.	2.9	7
96	Hybrid Multimodal Imaging Synthons for Chemoselective and Efficient Biomolecule Modification with Chelator and Near-Infrared Fluorescent Cyanine Dye. Pharmaceuticals, 2020, 13, 250.	1.7	7
97	αvβ3-Specific Gold Nanoparticles for Fluorescence Imaging of Tumor Angiogenesis. Nanomaterials, 2021, 11, 138.	1.9	7
98	Design, Synthesis, In Vitro and In Vivo Evaluation of Heterobivalent SiFAlin-Modified Peptidic Radioligands Targeting Both Integrin αvβ3 and the MC1 Receptor—Suitable for the Specific Visualization of Melanomas?. Pharmaceuticals, 2021, 14, 547.	1.7	7
99	Molecular imaging of cardiac CXCR4 expression in a mouse model of acute myocardial infarction using a novel 68Ga-mCXCL12 PET tracer. Journal of Nuclear Cardiology, 2021, 28, 2965-2975.	1.4	6
100	Synthesis, characterization and optimization of <i>in vitro</i> properties of NIR-fluorescent cyclic α-MSH peptides for melanoma imaging. Journal of Materials Chemistry B, 2020, 8, 10602-10608.	2.9	6
101	Synthesis and Preclinical Evaluation of [¹⁸ F]SiFA-PSMA Inhibitors in a Prostate Cancer Model. Journal of Medicinal Chemistry, 2021, 64, 15671-15689.	2.9	6
102	Improving the stability of peptidic radiotracers by the introduction of artificial scaffolds: which structure element is most useful?. Journal of Labelled Compounds and Radiopharmaceuticals, 2015, 58, 395-402.	0.5	4
103	Aiming at the tumor-specific accumulation of MGMT-inhibitors: First description of a synthetic strategy towards inhibitor-peptide conjugates. Tetrahedron Letters, 2020, 61, 151840.	0.7	4
104	Synthesis, in vitro and in vivo evaluation of 18 F-fluoronorimatinib as radiotracer for Imatinib-sensitive gastrointestinal stromal tumors. Nuclear Medicine and Biology, 2018, 57, 1-11.	0.3	3
105	Lewis Acid-Facilitated Radiofluorination of MN3PU: A LRRK2 Radiotracer. Molecules, 2020, 25, 4710.	1.7	3
106	Evaluation of WO2015042088 A1 - a novel urea-based scaffold for TrkA inhibition. Expert Opinion on Therapeutic Patents, 2016, 26, 291-295.	2.4	2
107	Synthesis of 2-Fluoroacetoacetic Acid and 4-Fluoro-3-hydroxyÂbutyric Acid. Synthesis, 2019, 51, 2351-2358.	1.2	2

#	Article	IF	CITATIONS
109	Identification of a Suitable Peptidic Molecular Platform for the Development of NPY(Y 1)Râ€&pecific Imaging Agents. ChemMedChem, 2020, 15, 1652-1660.	1.6	2
110	Synthesis and <i>in vivo</i> evaluation of a radiofluorinated ketone body derivative. RSC Medicinal Chemistry, 2020, 11, 297-306.	1.7	2
111	¹⁸ F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor (SiFA) for Positron Emission Tomography. Journal of Visualized Experiments, 2020, , .	0.2	2
112	PESIN Conjugates for Multimodal Imaging: Can Multimerization Compensate Charge Influences on Cell Binding Properties? A Case Study. Pharmaceuticals, 2021, 14, 531.	1.7	2
113	Efficient and Mild Ytterbium(III)-Catalyzed Tosylation of Alcohols. Synthesis, 2004, 2004, 885-888.	1.2	1
114	Synthetic approaches towards [18 F]fluoro-DOG1, a potential radiotracer for the imaging of gastrointestinal stromal tumors. Tetrahedron Letters, 2018, 59, 3332-3335.	0.7	1
115	GlucoSiFA and LactoSiFA: New Types of Carbohydrate-Tagged Silicon-Based Fluoride Acceptors for 18F-Positron Emission Tomography (PET). Synthesis, 2019, 51, 1196-1206.	1.2	1
116	On the Viability of Tadalafil-Based 18F-Radiotracers for In Vivo Phosphodiesterase 5 (PDE5) PET Imaging. ACS Omega, 2021, 6, 21741-21754.	1.6	1
117	Are heterobivalent GRPR- and VPAC1R-bispecific radiopeptides suitable for efficient in vivo tumor imaging of prostate carcinomas?. Bioorganic and Medicinal Chemistry Letters, 2021, 48, 128241.	1.0	1